Related Experiment Video

Updated: Jul 10, 2026

Assessment of Antibody-based Drugs Effects on Murine Bone Marrow and Peritoneal Macrophage Activation
10:35

Assessment of Antibody-based Drugs Effects on Murine Bone Marrow and Peritoneal Macrophage Activation

Published on: December 26, 2017

Thiazolidinediones as anti-inflammatory and anti-atherogenic agents

Antonio Ceriello1

  • 1Warwick Medical School, Clinical Sciences Research Institute, University Hospital, Coventry, Warwickshire, UK. antonio.ceriello@warwick.ac.uk

Diabetes/Metabolism Research and Reviews
|November 9, 2007
PubMed

Insights

Thiazolidinediones (TZDs) may impact cardiovascular outcomes in type 2 diabetes by reducing oxidative stress and inflammation. This review discusses their anti-inflammatory and anti-atherogenic properties, focusing on rosiglitazone and pioglitazone.

Area of Science:

  • Endocrinology
  • Cardiology
  • Pharmacology

Background:

  • Type 2 diabetes is linked to cardiovascular disease due to insulin resistance, hyperglycemia, oxidative stress, and inflammation.
  • Oxidative stress contributes to endothelial dysfunction and atherosclerosis in diabetic patients.
  • Inflammatory factors are elevated in type 2 diabetes, increasing risks of atherothrombosis and plaque rupture.

Purpose of the Study:

  • To review the impact of thiazolidinediones (TZDs) on cardiovascular outcomes in type 2 diabetes.
  • To explore the anti-inflammatory and anti-atherogenic properties of TZDs.
  • To discuss the cardiovascular profiles of rosiglitazone and pioglitazone.

Main Methods:

  • Literature review of studies on TZDs and cardiovascular outcomes in type 2 diabetes.
  • Analysis of data concerning the effects of rosiglitazone and pioglitazone on cardiovascular risk factors.
  • Examination of evidence for anti-inflammatory and anti-atherogenic mechanisms of TZDs.

Main Results:

  • TZDs are used to manage glucose levels and may influence other cardiovascular risk factors.
  • Emerging data suggests TZDs possess anti-inflammatory and anti-atherogenic properties.
  • Cardiovascular outcome profiles of rosiglitazone and pioglitazone are under investigation.

Conclusions:

  • TZDs may offer benefits beyond glucose control for cardiovascular health in type 2 diabetes.
  • Further research is needed to fully elucidate the cardiovascular effects of TZDs.
  • Understanding the mechanisms of TZDs is crucial for managing macrovascular complications in diabetes.

Related Concept Videos

Oral Hypoglycemic Agents: Biguanides and Glitazones01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood glucose levels...
Antihypertensive Drugs: Thiazide-Class Diuretics01:15

Antihypertensive Drugs: Thiazide-Class Diuretics

Thiazide diuretics are sulfonamide derivatives featuring a benzothiadiazine ring system in their molecular structure. Based on this structure, thiazide diuretics can be categorized into two groups: thiazide-type and thiazide-like diuretics. Thiazide-type diuretics, including hydrochlorothiazide and chlorothiazide, consist of a benzothiadiazine backbone with an attached sulfonamide group. Thiazide-like diuretics, such as chlorthalidone and indapamide, lack the thiazide ring but demonstrate...
Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a significant...
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors01:19

Oral Hypoglycemic Agents: α-Glucosidase Inhibitors

α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are typically...
Oral Hypoglycemic Agents: Sulfonylureas01:17

Oral Hypoglycemic Agents: Sulfonylureas

Sulfonylureas are oral hypoglycemic agents utilized in treating type 2 diabetes. They are characterized by their unique sulfonylurea chemical structure. The family of sulfonylureas is divided into generations. First-generation sulfonylureas, including tolbutamide (Orinase), chlorpropamide (Diabinese), and tolazamide (Tolinase), trigger insulin release from pancreatic β cells and enhance peripheral tissues' insulin sensitivity. The second-generation members, such as glipizide (Glucotrol),...
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...